Anson Funds
Anson Funds is an investment management firm established in 2003 and headquartered in Dallas, Texas, with an additional office in Toronto, Canada. The firm manages over $1.5 billion in assets, focusing on publicly traded equity and debt securities globally. Anson Funds employs a variety of investment strategies, including long/short equity, event-driven, distressed situations, capital structure arbitrage, and relative value approaches, often adopting a long bias toward public equities and fixed-income markets. The firm aims to deliver net-of-fees performance characterized by low volatility and low correlations to broader market indexes. Anson Funds has gained recognition in the financial industry, receiving a Top 10 Hedge Fund ranking by Barclay Managed Fund from 2018 to 2020, and has been featured in prominent publications such as Barron’s and Bloomberg. Its flagship fund, launched in 2007, is complemented by other hedge funds focusing on real estate and tactical equity strategies.
InterRent REIT
Post in 2025
InterRent REIT is a real estate investment trust focused on enhancing Unitholder value through the acquisition and ownership of multi-residential properties across Canada. The organization aims to expand its portfolio in markets with stable vacancies and sufficient available units to facilitate effective management. InterRent's primary goals include providing Unitholders with stable and growing cash distributions from a diversified property portfolio, enhancing asset value through active management, and increasing distributable income via strategic acquisitions. Revenue is generated from rental income as well as ancillary services such as parking and laundry. The company emphasizes a conservative payout ratio to maintain a healthy balance sheet while pursuing growth.
NRx Pharmaceuticals
Post in 2025
NRx Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing innovative therapeutics for central nervous system disorders and life-threatening pulmonary diseases. The company aims to address serious medical conditions that often lack effective treatments. It has commercialized ZYESAMI (Aviptadil), a therapeutic for COVID-related respiratory failure, and is advancing NRX-100/101, which represents the first sequential drug regimen targeting bipolar depression in patients experiencing acute suicidal ideation and behavior. Additionally, NRx Pharmaceuticals has been awarded exclusive worldwide rights by the Government of Israel to develop and market the BriLife COVID vaccine, enhancing its portfolio in the fight against respiratory illnesses.
LionsGate Entertainment
Post in 2024
Lions Gate Entertainment Corp. is a global content company engaged in the production and distribution of motion pictures, television programming, and digital content. Founded in 1986 and headquartered in Santa Monica, California, the company operates through three main segments: Motion Picture, Television Production, and Media Networks. The Motion Picture segment focuses on developing and producing feature films, including acquiring distribution rights and licensing films worldwide. The Television Production segment develops, produces, and distributes various television content, including series and non-fiction programming, while also managing the licensing of its original productions. This segment generates significant revenue by syndicating approximately 70 television shows across multiple networks. The Media Networks segment facilitates the distribution of STARZ branded premium subscription services both domestically and internationally, enhancing its presence in the streaming market. Lionsgate is recognized for its commitment to bold and innovative entertainment, appealing to diverse audiences globally.
NRx Pharmaceuticals
Post in 2024
NRx Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing innovative therapeutics for central nervous system disorders and life-threatening pulmonary diseases. The company aims to address serious medical conditions that often lack effective treatments. It has commercialized ZYESAMI (Aviptadil), a therapeutic for COVID-related respiratory failure, and is advancing NRX-100/101, which represents the first sequential drug regimen targeting bipolar depression in patients experiencing acute suicidal ideation and behavior. Additionally, NRx Pharmaceuticals has been awarded exclusive worldwide rights by the Government of Israel to develop and market the BriLife COVID vaccine, enhancing its portfolio in the fight against respiratory illnesses.
View, Inc., established in 2006 and headquartered in Milpitas, California, specializes in designing and manufacturing intelligent glass systems for various sectors, including workplace, healthcare, education, and hospitality. The company's flagship product, View Smart Windows, employs AI to automatically adjust in response to sunlight, enhancing natural light access and occupant experience, while minimizing heat and glare, and reducing energy consumption. Each View installation also includes a cloud-connected smart building platform, enabling further building optimization. With operations in the U.S. and internationally, View has improved over 90 million square feet of buildings, ranging from offices to multifamily residences.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.